Cargando…

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

BACKGROUND: Due to recent concerns about the toxicity of trastuzumab emtansine (T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-DM1 and stereotactic radiation. METHODS: This is a single institution series...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mills, Matthew N., Walker, Chelsea, Thawani, Chetna, Naz, Afrin, Figura, Nicholas B., Kushchayev, Sergiy, Etame, Arnold, Yu, Hsiang-Hsuan Michael, Robinson, Timothy J., Liu, James, Vogelbaum, Michael A., Forsyth, Peter A., Czerniecki, Brian J., Soliman, Hatem H., Han, Hyo S., Ahmed, Kamran A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934378/ https://www.ncbi.nlm.nih.gov/pubmed/33663447 http://dx.doi.org/10.1186/s12885-021-07971-w

Ejemplares similares

Capecitabine and stereotactic radiation in the management of breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
por: Corbin, Kimberly S., et al.
Publicado: (2020)

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
por: Akyildiz, Arif, et al.
Publicado: (2023)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
por: Kim, Chung Young, et al.
Publicado: (2019)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
por: Liu, Peipei, et al.
Publicado: (2020)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies
por: Rubino, Sebastian, et al.
Publicado: (2022)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
por: Jeon, Eun-Jeong, et al.
Publicado: (2023)

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
por: Chung, Yuan-Chiang, et al.
Publicado: (2015)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
por: Sharp, Adam, et al.
Publicado: (2015)

The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
por: Yan, Hongjing, et al.
Publicado: (2017)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
por: Chen, Liuxi, et al.
Publicado: (2016)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_29be48hf3hsvthfp82ie3alc89